Merz Therapeutics’ XEOMIN® (incobotulinumtoxinA) receives new therapeutic indication for the United Kingdom
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the use of XEOMIN® for the treatment of focal spasticity of the lower limb affecting the ankle joint. The approval, which previously included upper limb spasticity, has now been extended, enabling Merz Therapeutics to offer holistic support to people in the UK living with spasticity who require comprehensive treatment.
“The label extension in the UK is an important step for Merz Therapeutics and the patients that we serve. With the UK becoming the second market, following Japan, to grant approval for the treatment of lower limb spasticity, affecting the ankle joint, it establishes the UK as the pioneering European country in this area. This approval supports our strong commitment to bringing better outcomes to more patients,” says Stefan König, CEO Merz Therapeutics.
Enabling holistic treatment for people living with spasticity
Lower limb spasticity is a consequence of upper motor neuron damage as may occur following e.g. a stroke. Each year, around 41,800 people in England have a stroke that results in spasticity, approximately 66 % of which suffer from spasticity in the ankle.1 XEOMIN ® with the active ingredient incobotulinumtoxinA is injected intramuscularly to improve tone. Appropriately qualified healthcare practitioners can now use XEOMIN ® to treat lower and upper limbs individually or concomitantly, adjusting the dosage as needed.
John Lambert, Country Manager of Merz Therapeutics UK & Ireland: “This new therapeutic indication supports an extension of the benefit XEOMIN® can bring in the treatment of spasticity. We are very proud that we can now offer an alternative product to help patients in the UK.”
With the new therapeutic indication, the maximum dose of XEOMIN® for the treatment of the lower limb is 400 units per injection. For the combined treatment of upper and lower limb spasticity, the maximum dose per administration is 500 units for the first injection and rising to 600 units for following injections. Accepting that patients should always be administered the lowest effective dose possible, with an increase in total dose patients can now be treated with XEOMIN® for more patterns of spasticity simultaneously than before this new indication. The dosing interval should be at least 12 weeks. The therapeutic indication is based on trial data from Japan, where XEOMIN ® was also approved for treatment of the lower limb region in 2021.
Going forward, Merz Therapeutics can thus offer UK patients being treated for their spasticity a more holistic solution for their treatment.
1. National Institute for Health and Care Excellence Draft scope for the proposed appraisal of botulinum toxin type A (Botox, Dysport and Xeomin) for treating upper and lower limb spasticity associated with stroke Issue Date: July 2014. Available at: https://www.nice.org.uk/guidance/gid-tag499/documents/spasticity-after-stroke-botulinum-toxin-type-a-draft-scope-for-consultation-prereferral-july-20142. (Accessed: 02 June, 2023).
About XEOMIN ®
XEOMIN® is effective by weakening the contraction of voluntary muscles. It relieves the muscle tone by inhibiting the release of a neurotransmitter called acetylcholine from the peripheral nerve endings. XEOMIN® is free from complexing proteins and has a low risk of neutralizing antibody formation. XEOMIN® is approved in more than 75 countries worldwide to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm and sialorrhea.
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.
Please visit www.merztherapeutics.com
About Merz
Merz Group is a global, diversified company with its headquarters in Frankfurt, Germany. Its commitment to innovation, long-term perspective, and focus on profitable growth depict the privately owned company that has been around for more than 110 years. Merz Group has the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate and Financial Investments. The company employs 3,969 people in 28 countries worldwide.
To learn more, please visit www.merz.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005580/en/
Contact information
Merz Therapeutics GmbH
Agnes Tesch
Global Communications
+49 69 1503 2129
agnes.tesch@merz.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice Introduces Industry’s First Small Embedded Vision FPGA with Integrated USB26.9.2023 23:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced the Lattice CrossLinkU™-NX FPGA family, the industry’s first FPGAs with integrated USB device functionality in their class. CrossLinkU-NX FPGAs help accelerate USB-equipped system designs and simplify thermal management through a combination of a hardened USB controller and physical layer (PHY), a unique low power standby mode, and a complete set of reference designs. Extending Lattice’s embedded vision sensor bridging leadership with USB host interfaces, CrossLinkU-NX FPGAs are designed to meet growing customer needs to simplify USB-based design for applications across the Computing, Industrial, Automotive, and Consumer markets. “Reducing power consumption, total cost of ownership, and design footprint are critical for expanding the potential of AI and vision applications,” said Dan Mansur, Vice President, Product Marketing, Lattice Semiconductor. “Lattice CrossLinkU-NX FPGAs are optimized to addr
Demand Increases for Project Professionals with AI Skills, Yet PMI Research Finds Only 18% Have Practical Experience26.9.2023 18:00:00 EEST | Press release
Project Management Institute (PMI), the world's leading organization for the project management profession, is empowering millions of global project professionals worldwide to adopt, embrace, and leverage artificial intelligence (AI), machine learning (ML), and generative AI (GenAI). PMI is developing the tools, resources, and learning opportunities – including a free, introductory online course entitled “Generative AI Overview for Project Managers” – project professionals need to leverage AI powered technology while preserving the human touch in project management. According to McKinsey, GenAI and other technologies have the potential to automate work activities that absorb 60 to 70 percent of employees’ time today. But tools cannot automate interpersonal skills, the invaluable and very necessary skills project managers bring to projects. Communication, problem-solving, collaborative leadership, and strategic thinking – skills PMI calls “power skills” – will continue to be crucial to
Aktana Announces New Strategy Suite to Give Biopharma Leaders Unprecedented Visibility and Control Over Omnichannel Campaign Effectiveness26.9.2023 18:00:00 EEST | Press release
Today, at the inaugural Aktana Innovation Exchange (AIx) event, Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, announced three new products that transform customer engagement programs by dynamically tightening the connection between strategy, tactical execution and time to impact. AIx is a collaborative event hosting executives from more than 35 life sciences and technology companies with the sole mission of improving the rate of innovation in applying AI and machine learning to commercial and medical programs. In recent research conducted by Aktana with 20 biopharma companies, more than 75% of respondents cited a severe challenge in achieving direct line of sight of how strategies are being executed in the field and knowing when tactics should be modified. The gap between strategy and delivering precision execution of pharmaceutical commercial campaigns is a constant hurdle across the industry, with new drug launches failing to meet
Improbable ventures into new worlds, unveils robust financial performance, underpinned by exciting innovation developments and standout progress made through recent sports events26.9.2023 17:30:00 EEST | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230926212157/en/ (Graphic: Business Wire) Highlights With a combination of gaming technology, new AI capabilities and metaverse infrastructure, the metaverse is delivering more interesting, exciting and useful experiences, boosted by the creator economy. For instance, sports has taken the lead in investments and ambitious projects, driven by the appetite of current and new fans for exclusive, fun content that enables them to consume their sport in a unique fashion with their community, and allowing rights owners new and innovative ways to monetize their content. Having completed its transformation, Improbable is now clarifying its brand mission as a venture builder, creating new ventures based upon its own backbone technology. The company has reorganized and now has three primary areas of activities: Metaverse technology development Metaverse and metaversal experiences developme
ClickHouse Announces ClickPipes: A Continuous Data Ingestion Service for ClickHouse Cloud26.9.2023 17:16:00 EEST | Press release
ClickHouse Inc., creator of the popular open-source columnar database designed for real-time analytics, today announces the general availability of ClickPipes, which connects external data sources directly into ClickHouse Cloud. ClickPipes allows users to set up continuous data pipelines in just a few clicks and launches with integrations for Confluent Cloud, Amazon MSK and Apache Kafka, with plans to add more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230926621382/en/ ClickPipes powers seamless data ingestion for real-time analytics (Graphic: Business Wire) “Setting up reliable data pipelines can be a tedious task. By providing a user-friendly continuous ingestion experience for ClickHouse Cloud, users can now focus on what really matters: extracting insights from their data,” says Aaron Katz, Co-founder and CEO of ClickHouse, Inc. “Besides its existing connectors, ClickPipes also represents the foundation of a serverl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom